Severe but Reversible Cholestatic Liver Injury after Pioglitazone Therapy

  1. Amar G. Pinto, MD;
  2. Oscar W. Cummings, MD; and
  3. Naga Chalasani, MD
  1. Indiana University School of Medicine; Indianapolis, IN 46202. (Pinto, Cummings, Chalasani)

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    TO THE EDITOR:

    Background: Pioglitazone, a second-generation thiazolidinedione, is commonly used in the management of type 2 diabetes mellitus. Unlike troglitazone, pioglitazone is generally …

    « Previous | Next Article »Table of Contents